WILLINGNESS TO PAY OF YOUNG GREEK WOMEN FOR THE NEW ANTI-HUMAN PAPILOMA VIRUS VACCINE

Author(s)

Theodoros Kalampokas, MD, MSc, PhD, Researcher1, Petros E. Maravelakis, PhD, Lecturer2, Susan Gregory, MRCTsych, MSc, Scientific collaborator1, Kostas Athanasakis, MSc, Research Assistant1, Mary Geitona, PhD, PhD3, John Kyriopoulos, MD, PhD, MD, PhD11National School of Public Health, Athens, Greece; 2 University of Aegean, Karlovasi Samou, Greece; 3 University of Thessaly, Volos, Greece

OBJECTIVES: To investigate the Willingness to Pay (WtP) of young Greek women for the new Anti-Human Papiloma Virus vaccine. METHODS: A sample of 1200 women aged 16-26 yrs old was chosen, representative to the Greek women's population. Two questions were posed to the study participants, after they have been informed about the current facts around cervical cancer, the anti-HPV vaccine and the potential benefits and side-effects of the vaccination. The two questions were: a) “How much do you believe a vaccine against HPV would cost?” and b) “How much would you be willing to pay in order to get such a vaccine?”. The estimation of women's WtP was based on the difference between both answers. When the (a)-(b) difference was positive, it was assumed that the respondent was not WtP for the vaccine, whereas when (a)-(b) was zero or negative, the respondent was perceived as WtP either the exact amount needed for the vaccine or more. RESULTS: Out of 1200 questionnaires administered, 812 were completed (response rate 68%). The distribution of the (a)-(b) differences showed that 63.5% of the women asked were WtP the exact amount they estimated needed for the vaccine. Another 25% were WtP even more. Only the remaining 11.5% were not eager to pay the price they thought the vaccine would have. CONCLUSION: A total of 88.5% of young Greek women was WtP the exact amount or even more than the amount declared that an Anti-HPV vaccine would cost. This finding demonstrates the necessity of introducing a country-wide vaccination program, since it seems to be cost–effective at this age group, as well as the acceptance of the majority to cover the related costs entirely by out –of- pocket payments.

Conference/Value in Health Info

2007-10, ISPOR Europe 2007, Dublin, Ireland

Value in Health, Vol. 10, No. 6 (November/December 2007)

Code

PIH22

Topic

Health Policy & Regulatory

Topic Subcategory

Public Spending & National Health Expenditures

Disease

Reproductive and Sexual Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×